<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>IHE &mdash; Blue Cross: drug affordability | Trader Notes</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: 'Lato', -apple-system, sans-serif; background: #FFF1E5; color: #1a1a2e; line-height: 1.6; }
        .container { max-width: 760px; margin: 0 auto; padding: 1.5rem; }
        a { color: #0d7680; }
    </style>
    <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@700&family=Lato:wght@300;400;700&display=swap" rel="stylesheet">
</head>
<body>
<div class="container">
    <div style="margin-bottom:1rem">
        <a href="../" style="font-size:0.8rem;color:#6b7280;text-decoration:none">&larr; Back to Trading Sheet</a>
    </div>

    <div style="display:flex;align-items:center;gap:12px;margin-bottom:0.5rem;flex-wrap:wrap">
        <span style="font-family:'Playfair Display',serif;font-size:1.8rem;font-weight:700">IHE</span>
        <span style="font-size:0.8rem;padding:4px 12px;border-radius:12px;color:#2563eb;background:#dbeafe;font-weight:700">TRADING</span>
        <span style="font-size:0.85rem;color:#6b7280">LONG 60% &middot; Band B</span>
    </div>
    <div style="font-size:1rem;color:#4b5563;margin-bottom:0.5rem">Blue Cross: drug affordability</div>

    <div style="display:flex;gap:1.5rem;flex-wrap:wrap;margin:1rem 0"><div><div style="font-size:0.7rem;color:#6b7280;text-transform:uppercase">DD Price</div><div style="font-weight:700;font-size:1.1rem">$90.38</div></div><div><div style="font-size:0.7rem;color:#6b7280;text-transform:uppercase">Entry Price</div><div style="font-weight:700;font-size:1.1rem">$90.38</div></div><div><div style="font-size:0.7rem;color:#6b7280;text-transform:uppercase">Current</div><div style="font-weight:700;font-size:1.1rem">$90.48</div></div><div><div style="font-size:0.7rem;color:#7c3aed;text-transform:uppercase">Report P&amp;L</div><div style="font-weight:700;font-size:1.1rem;color:#7c3aed">+0.1%</div></div><div><div style="font-size:0.7rem;color:#16a34a;text-transform:uppercase">Trade P&amp;L</div><div style="font-weight:700;font-size:1.1rem;color:#16a34a">+0.1%</div></div></div>
    <div style="margin:0.5rem 0"><span style="display:inline-block;padding:3px 10px;border-radius:12px;font-size:0.75rem;font-weight:700;color:#166534;background:#dcfce7">INTACT</span> <span style="display:inline-block;padding:3px 10px;border-radius:12px;font-size:0.75rem;font-weight:700;color:#92400e;background:#fef3c7">&#128264; stirring (2)</span></div>
    <div style="margin:1rem 0">
                <div style="font-size:0.75rem;color:#6b7280;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:4px">Conviction</div>
                <div style="display:flex;align-items:center;gap:10px">
                    <div style="flex:1;max-width:200px;height:8px;background:#e5e7eb;border-radius:4px;overflow:hidden">
                        <div style="width:70%;height:100%;background:#16a34a;border-radius:4px"></div>
                    </div>
                    <span style="color:#16a34a;font-weight:700;font-size:1.1rem">7/10</span>
                </div>
            </div>
    <div style="background:#f9fafb;border-radius:6px;padding:0.8rem 1rem;margin:0.8rem 0;font-size:0.85rem;color:#374151;border-left:3px solid #2563eb"><strong>Status:</strong> ENTERED: conviction 7/10, signal stirring, The original thesis regarding Blue Cross is gaining traction as niche sources begin to recognize the significance of affordability programs, including</div>
    <div style="margin:1rem 0;padding:1rem;background:#fefce8;border-radius:6px;border-left:3px solid #eab308"><div style="font-size:0.75rem;color:#92400e;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:6px">Original Report Thesis</div><div style="font-size:0.85rem;color:#374151;margin-bottom:6px"><strong>Mechanism:</strong> The signal is a concrete operational story: Blue Cross is described as implementing affordability programmes that include biosimilar expansion and a direct purchasing partnership (a “how the payer actually cuts costs” playbook rather than generic pricing rhetoric). The reason this can be bullish for a broad pharma basket, despite sounding adversarial, is that credible cost-control narratives can r</div><div style="font-size:0.85rem;color:#374151;margin-bottom:6px"><strong>Tripwire:</strong> Freshness is 55/100 with a “possible reprint” flag and an oldest-claim date of 2025-12-30, so the edge is not about speed; it is about the market underweighting payer execution as a driver of narrative and multiples. Upstream explicitly warns the instrument mapping could invert the exposure (i.e., p</div><div style="font-size:0.85rem;color:#374151;margin-bottom:6px"><strong>Evidence:</strong> The single hydrated artefact is the Detroit Chamber write-up describing a 15% pharmacy spending rise in 2024 and 2025 initiatives including biosimilar and direct purchasing, with the “less than 10% of brand cost” claim doing most of the work on mechanism. Source: detroitchamber.com.</div></div>
    <div style="background:#f0fdf4;border-radius:6px;padding:0.8rem 1rem;margin:0.8rem 0;font-size:0.85rem;border-left:3px solid #22c55e"><strong>&#128269; Watching For:</strong> I will be looking for further coverage from more mainstream financial news outlets or concrete data regarding impacts on costs associated with Blue Cross's initiatives. Key metrics on pharmacy spending would be beneficial.</div>
    <div style="background:#fff7ed;border-radius:6px;padding:0.8rem 1rem;margin:0.8rem 0;font-size:0.85rem;border-left:3px solid #f97316"><strong>&#9888; Concerns:</strong> The main concerns remain political backlash and the risk of the narrative losing momentum if it doesn't gain traction in broader media outlets. There's also a fear that if PBM-bypass strategies don't deliver promised cost reductions, skepticism may increase.</div>
    <div style="margin:1.5rem 0"><div style="font-size:0.8rem;color:#6b7280;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:0.8rem;padding-bottom:4px;border-bottom:1px solid #e5e7eb">Private Narrative Log</div><div style="margin-bottom:1rem;padding:0.8rem 1rem;background:white;border-radius:6px;border-left:3px solid #d1d5db;box-shadow:0 1px 2px rgba(0,0,0,0.04)"><div style="font-size:0.85rem;color:#374151;line-height:1.6">I'm feeling stable about my thesis despite the lack of immediate price movement. The mechanism still seems valid, as Blue Cross's operational changes could foster a political narrative that supports drug affordability, which is crucial for the healthcare sector. The recent media coverage is stirring the narrative which is an encouraging sign, but I recognize that the market's formal acknowledgment is still forthcoming. I will continue to monitor this situation over the next cycle as price stability suggests there may be less immediate seller pressure.</div><div style="font-size:0.7rem;color:#9ca3af;margin-top:4px">Cycle 2 &middot; 2026-02-19T19:53</div></div><div style="margin-bottom:1rem;padding:0.8rem 1rem;background:white;border-radius:6px;border-left:3px solid #d1d5db;box-shadow:0 1px 2px rgba(0,0,0,0.04)"><div style="font-size:0.85rem;color:#374151;line-height:1.6">This thesis appears to have a solid foundation as it encapsulates real operational changes that Blue Cross is pursuing to enhance drug affordability. The recent coverage is promising, showing that the narrative is stirring within the niche healthcare media. I feel like I have a good conviction at this point to enter the trade, especially since price has remained stable and the news cycle is beginning to acknowledge the importance of these initiatives. Drawing attention to potential cost control for pharma is always a relevant topic, and I feel it might alleviate some risk aversion in the secto</div><div style="font-size:0.7rem;color:#9ca3af;margin-top:4px">Cycle 1 &middot; 2026-02-19T17:02</div></div></div>
    <div style="margin:1.5rem 0"><div style="font-size:0.8rem;color:#6b7280;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:0.8rem;padding-bottom:4px;border-bottom:1px solid #e5e7eb">Due Diligence Log</div><div style="margin-bottom:0.8rem;padding:0.6rem 1rem;background:#f9fafb;border-radius:6px;border-left:3px solid #16a34a"><div style="display:flex;justify-content:space-between;align-items:center;margin-bottom:4px"><span style="font-weight:700;color:#16a34a">TRADE</span><span style="font-size:0.7rem;color:#9ca3af">pre_trade &middot; </span></div><div style="font-size:0.82rem;color:#374151">Fresh signal (3h), price stable (0.0% move), confidence 60%</div><div style="font-size:0.72rem;color:#6b7280;margin-top:3px">Price: $90.38 | Move: 0.0% | Staleness: 3h</div></div><div style="margin-bottom:0.8rem;padding:0.6rem 1rem;background:#f9fafb;border-radius:6px;border-left:3px solid #16a34a"><div style="display:flex;justify-content:space-between;align-items:center;margin-bottom:4px"><span style="font-weight:700;color:#16a34a">TRADE</span><span style="font-size:0.7rem;color:#9ca3af">watch_check &middot; </span></div><div style="font-size:0.82rem;color:#374151">Fresh signal (3h), price stable (0.0% move), confidence 60%</div><div style="font-size:0.72rem;color:#6b7280;margin-top:3px">Price: $90.38 | Move: 0.0% | Staleness: 3h</div></div></div>
    <div style="margin:1.5rem 0"><div style="font-size:0.8rem;color:#6b7280;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:0.8rem;padding-bottom:4px;border-bottom:1px solid #e5e7eb">Price History</div><div style="display:flex;flex-wrap:wrap;gap:6px"><span style="font-size:0.7rem;color:#f59e0b;padding:2px 6px;background:#f9fafb;border-radius:4px">14:21 $90.38 +0.0%</span><span style="font-size:0.7rem;color:#f59e0b;padding:2px 6px;background:#f9fafb;border-radius:4px">15:21 $90.38 +0.0%</span><span style="font-size:0.7rem;color:#f59e0b;padding:2px 6px;background:#f9fafb;border-radius:4px">16:21 $90.38 +0.0%</span><span style="font-size:0.7rem;color:#f59e0b;padding:2px 6px;background:#f9fafb;border-radius:4px">17:22 $90.38 +0.0%</span><span style="font-size:0.7rem;color:#f59e0b;padding:2px 6px;background:#f9fafb;border-radius:4px">18:22 $90.38 +0.0%</span><span style="font-size:0.7rem;color:#f59e0b;padding:2px 6px;background:#f9fafb;border-radius:4px">19:23 $90.38 +0.0%</span><span style="font-size:0.7rem;color:#f59e0b;padding:2px 6px;background:#f9fafb;border-radius:4px">20:23 $90.38 +0.0%</span><span style="font-size:0.7rem;color:#16a34a;padding:2px 6px;background:#f9fafb;border-radius:4px">21:23 $90.46 +0.1%</span><span style="font-size:0.7rem;color:#16a34a;padding:2px 6px;background:#f9fafb;border-radius:4px">22:24 $90.46 +0.1%</span><span style="font-size:0.7rem;color:#16a34a;padding:2px 6px;background:#f9fafb;border-radius:4px">23:25 $90.48 +0.1%</span><span style="font-size:0.7rem;color:#16a34a;padding:2px 6px;background:#f9fafb;border-radius:4px">00:26 $90.48 +0.1%</span></div></div>

    <div style="margin-top:2rem;padding-top:1rem;border-top:1px solid #e5e7eb;font-size:0.72rem;color:#9ca3af;text-align:center">
        Position #222 &middot; Updated 2026-02-20 00:52 UTC &middot; <a href="../" style="color:#9ca3af">Back to Trading Sheet</a>
    </div>
</div>
</body>
</html>